-

Simulations Plus to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the following investor events in September:

2025 Wells Fargo Healthcare Conference
Format: Fireside chat and one-on-one meetings
When: Wednesday and Thursday, September 3-4, 2025
Location: Boston, Massachusetts
Webcast Link: Wednesday, September 3, 2025 at 12:45 PM ET here

Morgan Stanley 23rd Annual Global Healthcare Conference
Format: Fireside chat and one-on-one meetings
When: Wednesday, September 10, 2025
Location: New York City
Webcast Link: Wednesday, September 10, 2025 at 2:35 PM ET here

For more information about the events or questions about registration, interested parties should reach out to their contacts at Wells Fargo and Morgan Stanley.

About Simulations Plus, Inc.

With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update.

Contacts

Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com

Industry:

Simulations Plus, Inc.

NASDAQ:SLP
Release Versions
English

Contacts

Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com

More News From Simulations Plus, Inc.

Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will host a virtual Investor Day on Wednesday, January 21, 2026. The event will offer investors and analysts an in-depth look at the Company’s long-term strategy, product roadmap, and financial outlook, as well as a Q&A session with the execu...

Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and...

Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial Highlights (as compared to fourth quarter 2024) Total revenue decreased 6% to $17.5 million Software rev...
Back to Newsroom